Authors: Aihua Zhang Guangli Yan Ying Han Xijun Wang
Publish Date: 2014/05/18
Volume: 174, Issue: 1, Pages: 6-12
Abstract
Prostate cancer is a leading cause of cancer deaths in men worldwide Although prostatespecific antigen PSA has been extensively used as a serum biomarker to detect prostate cancer this screening method has suffered from a lack of specificities and sensitivities The successful prevention and treatment of prostate cancer relies on the early and accurate detection of the disease therefore more sensitive biomarkers are urgently needed Prostate has long been known to exhibit unique metabolite profiles fortunately metabolomics the study of all metabolites produced in the body can be considered most closely related to a patient’s phenotype It may provide clinically useful biomarkers applied toward identifying metabolic alterations in prostate cancer and has introduced new insights into the pathology of prostate cancer This advanced bioanalytic method may now open door for diagnostics Metabolomics has a great and largely potential in the field of disease and the analysis of the cancer metabolome to identify novel biomarkers and targets can now be undertaken in many research laboratories In this review we take a closer look at the metabolomics in the field of prostate cancer and highlight the interesting publications as references for the interested readerThis work was supported by the grants from the Key Program of Natural Science Foundation of State Grant No 90709019 81173500 81373930 81302905 81102556 81202639 National Key Technology Research and Development Program of the Ministry of Science and Technology of China Grant No 2011BAI03B03 2011BAI03B06 2011BAI03B08 National Key Subject of Drug Innovation Grant No 2009ZX09502005 and Foundation of Heilongjiang University of Chinese Medicine Grant no 201209
Keywords: